Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants

Enliven Therapeutics, Inc.

Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.
Underwriters granted 30-day option to purchase additional 1.53M shares; expected close June 16, 2025.
Net proceeds including option exercise expected ~$216.1M, for working capital and general corporate purposes.
Joint book-runners: Jefferies, Goldman Sachs, TD Cowen, Mizuho; LifeSci Capital as lead manager.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.